The P-III (EAGLE-1) study assessed the safety & efficacy of gepotidacin (2 doses of 3,000mg, oral) vs ceftriaxone (500mg, IM) + azithromycin (1,000mg) to treat uncomplicated urogenital gonorrhoea patients (n=~600). 1EP was microbiological response at the ToC visit 3-7 days post treatment
The study demonstrated drug’s non-inferiority with a success rate of 92.6% vs 91.2% for the combination of ceftriaxone & azithromycin
Moreover, the company concluded EAGLE-2 & EAGLE-3 studies assessing the safety & efficacy of gepotidacin (1,500mg, oral, BID for 5 days) vs nitrofurantoin (100mg, oral, BID for 5 days) to treat uncomplicated urinary tract infections (uUTI). The data was featured at ECCMID 2023 & published in The Lancet
Ref: GSK | Image: GSK
Related News:- GSK Reports Results from the P-III (EAGLE-1) Study of Gepotidacin for the Treatment of Urogenital Gonorrhoea (GC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
